News - Page 104 - Psychedelic Alpha

Our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.

Read more about the article U.S. Patent Grant to Strengthen Small Pharma’s DMT Patent Strategy With Injectable Formulation

U.S. Patent Grant to Strengthen Small Pharma’s DMT Patent Strategy With Injectable Formulation

Post published:July 27, 2022
Post category:Press Release

Read more about the article COMPASS Pathways plc to announce second quarter 2022 financial results on 4 August 2022

COMPASS Pathways plc to announce second quarter 2022 financial results on 4 August 2022

Post published:July 26, 2022
Post category:Press Release

Read more about the article HAVN Life Announces Financing Commitment of CAD$9,000,000 through the issuance of Convertible Debentures and Warrants

HAVN Life Announces Financing Commitment of CAD$9,000,000 through the issuance of Convertible Debentures and Warrants

Post published:July 24, 2022
Post category:Press Release

Read more about the article Incannex Receives Ethics Approval to Commence Phase 1 Clinical Trial of Multi-Use Anti-Inflammatory Drug IHL-675A

Incannex Receives Ethics Approval to Commence Phase 1 Clinical Trial of Multi-Use Anti-Inflammatory Drug IHL-675A

Post published:July 23, 2022
Post category:Press Release

Read more about the article COMPASS Pathways appoints Kabir Nath as Chief Executive Officer

COMPASS Pathways appoints Kabir Nath as Chief Executive Officer

Post published:July 20, 2022
Post category:Press Release

Read more about the article Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs

Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs

Post published:July 20, 2022
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of Ifenprodil for Idiopathic Pulmonary Fibrosis and Chronic Cough

Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of Ifenprodil for Idiopathic Pulmonary Fibrosis and Chronic Cough

Post published:July 19, 2022
Post category:Press Release

Read more about the article Psychedelic Investor Pulse Survey Results (Summer 2022)

Psychedelic Investor Pulse Survey Results (Summer 2022)

Post published:July 19, 2022
Post category:Uncategorized

Read more about the article George Tziras to Succeed Peter Rands as Small Pharma Chief Executive Officer

George Tziras to Succeed Peter Rands as Small Pharma Chief Executive Officer

Post published:July 18, 2022
Post category:Press Release

Read more about the article Small Pharma Reports Fiscal First Quarter 2023 Highlights

Small Pharma Reports Fiscal First Quarter 2023 Highlights

Post published:July 17, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.